View Older Stories View More Recent Stories
-
Amgen (AMGN): Tezspire Met Both Co-primary Endpoints In Phase 3 Trial For Chronic Rhinosinusitis With Nasal Polyps
-
Amgen (AMGN) Tops Q3 EPS by 47c; offers guidance
-
Amgen (AMGN) November 1 weekly option implied volatility into quarter results
-
Amgen (AMGN) option IV at high end of range into quarter results
-
Amgen (AMGN) Declares $2.25 Quarterly Dividend; 2.8% Yield
-
Amgen (AMGN) Launches Pavblu As Rival To Regeneron's (REGN) Eylea - Bloomberg
-
Amgen (AMGN) PT Raised to $383 at TD Cowen
-
Goldman Sachs Reiterates Conviction Buy Rating on Amgen (AMGN)
-
TD Cowen Reiterates Buy Rating on Amgen (AMGN)
-
Amgen (AMGN) presents positive top-line results from the Phase 3 MINT trial
-
Truist Securities Downgrades Amgen (AMGN) to Hold
-
Amgen (AMGN) October 350 and 360 calls active as share price down 5.3%
-
Goldman Sachs Reiterates Buy Rating on Immunovant (IMVT)
-
TD Cowen Reiterates Buy Rating on Amgen (AMGN)
-
BMO Capital Reiterates Outperform Rating on Amgen (AMGN)
-
Piper Sandler Reiterates Overweight Rating on Amgen (AMGN)
-
Baird Reiterates Underperform Rating on Amgen (AMGN)
-
Truist Securities Reiterates Buy Rating on Amgen (AMGN)
-
Amgen (AMGN) Tepezza Receives Approval In Japan For The Treatment Of Active Thyroid Eye Disease
-
Amgen (AMGN) To Host Conference Call To Discuss New Topline Data In Inflammation And Rare Disease
-
Oppenheimer Reiterates Outperform Rating on Amgen (AMGN)
-
Amgen (AMGN): Otezla Now Available In The U.S. For Moderate To Severe Pediatric Plaque Psoriasis
-
TD Cowen Reiterates Buy Rating on Amgen (AMGN)
-
Midday movers: Super Micro Computer, Airbnb and Lyft fall; Shopify rises
-
Amgen (AMGN) PT Raised to $381 at TD Cowen
-
Amgen (AMGN) PT Raised to $362 at RBC Capital
-
Stocks expected to have increasing option volume: AMGN ABNB FTNT SMCI RIVN TOST RDDT WYNN VFC CRUS IAC TRIP
-
Wells Fargo Downgrades Amgen (AMGN) to Equal Weight
-
Amgen (AMGN) Misses Q2 EPS by 1c; updates guidance
-
Amgen (AMGN) Declares $2.25 Quarterly Dividend; 2.7% Yield
-
RBC's biotech survey shows investors more bearish vs. last time
-
10 policies if Trump wins and stock implications: Jefferies
-
Deutsche Bank Reiterates Hold Rating on Amgen (AMGN)
-
Amgen (AMGN) PT Raised to $337 at UBS
-
2Q24 U.S. biotech earnings preview
-
Jefferies Reiterates Buy Rating on Amgen (AMGN)
-
Amgen (AMGN) option implied volatility flat
-
Amgen (AMGN) PT Raised to $340 at Argus
-
Amgen (AMGN) PT Raised to $332 at RBC Capital

